I love stem cells, but I have to admit bionics is totally amazing as well. Both hold great promise for fixing up human beings as we injured or age. Today a major advance in vision correction via bionics was announced here at UC Davis that has really caught my attention. I was not involved in …
Bionic eye here at UC Davis holds great promise for restoring vision Read More »
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper, …
About two months about Geron shocked and disappointed the stem cell community by dropping its stem cell program. The move was reportedly made for financial, not scientific reasons. Biotech companies have to be financially sound in order to help stem cell researchers turn science into cures and Geron’s leadership had to do what it thought …
What does Geron’s departure mean for ACT? Some perspectives Read More »
Sometimes a top scientist makes news with a quote on research and that happened with Ian Wilmut recently on stem cells. Move away from research on human ES cells (hESC) in favor of very new and still largely unclear trans-differentiation technology? I say, no way. But, Bradley Fikes of the North County Times has reported …
Ian Wilmut, Dolly’s dad, says dump hESC? What does this mean? Read More »
Reportedly, Geron has decided to only focus on cancer research and for financial reasons has shut down its hESC trial for spinal cord injury. This is a very sad day for stem cell science. (Update in 2020: the firm still exists, but is working in different areas. The stock has struggled.) No more spinal cord …
Bad news as Geron to quit hESC SCI trial for financial reasons Read More »
In mid-November the Catholic Church, in fact the Vatican itself, will do something it has never done before in its very long existence. It will hold a conference on stem cells. Perhaps equally unusual and of interest is the fact that the basis for this conference is a $1 million (USD) gamble by the Vatican …
More on the Vatican $1 million gamble on NeoStem and their upcoming conference in Rome Read More »
Advanced Cell Technology (ACT) announced today that it has treated two patients in its clinical trials: one for Stargardt’s Macular Dystrophy (see official trial page for a lot more info) and one for Dry Age-Related Macular Degeneration (see official trial page here for a lot more info). The patients underwent the treatment at UCLA and each …
The CIRM Board is meeting today and will decide on its future Chair via an election. There are two candidates, Jonathan Thomas (nominated by Bill Lockyer, the California state treasurer) and Frank Litvack, nominated by state controller, John Chang. Thomas is described as a Bond financier, while Litvack is an L.A. cardiologist and businessman with …
CIRM announced two sets of awards today that both should make major impact including its first clinical trial via Geron and $38 million for 27 basic biology studies. First Clinical Trial. Today CIRM awarded $25 million to support Geron’s FDA-approved clinical trial for spinal cord injury. This is CIRM’s first award to a for-profit company …
CIRM funds $25 million for Geron trial, $38 million for basic biology Read More »
The FDA has given Advanced Cell Technology (ACT) the go ahead to begin their clinical trial using retinal progenitor cells derived from hESC by clearing the company’s IND application, bringing hope to those with vision loss and even blindness. The trial will be a combined Phase I/II to treat Stargardt’s Macular Dystrophy and has huge …